Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/11/2017
SIETES contiene 92130 citas

 
 
 1 a 20 de 3005 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. FDA to evaluate increased risk of heart -related death and death from all causes with the gout medicine febuxostat (Uloric). FDA U.S. Food and Drug Administration 2017:15 de noviembre. [Ref.ID 102144]
2. Cita con resumen
Anónimo. FDA approves first digital pill. DIA Daily 2017:1. [Ref.ID 102142]
3. Cita con resumen
Casassus B. Contraception implant removed from global market. Lancet 2017;390:1576. [Ref.ID 102079]
4. Cita con resumen
Edwards IR. A new Erice report considering the safety of medicines in the 21st Century. Drug Saf 2017;40:845-9. [Ref.ID 102074]
5. Cita con resumen
Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. N Engl J Med 2017;377:1114-7. [Ref.ID 102072]
7. Cita con resumen
Morkem R, Williamson T, Patten S, Queenan JA, Wong ST, Manca D, Barber D. Trends in antidepressant prescribing to children and adolescents in Canadian primary care: A time-series analysis. Pharmacoepidemiol Drug Saf 2017;26:1093-9. [Ref.ID 102065]
8. Cita con resumen
Anónimo. FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease. FDA U.S. Food and Drug Administration 2017:21 de septiembre. [Ref.ID 102061]
11.Enlace a cita original Cita con resumen
Prasad V, Mailan S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med 2017;177:1569-75. [Ref.ID 102051]
12. Cita con resumen
Anónimo. FDA Approves CAR-T therapy for treatment of childhood leukemia. DIA Daily 2017:1. [Ref.ID 102036]
14. Cita con resumen
15. Cita con resumen
Russo EB. Cannabidiol claims and misconceptions. Trends Pharmacol Sci 2017;38:198-201. [Ref.ID 101988]
16. Cita con resumen
Rosenberg HG, Shnier A. Regulatory data are hidden in plain sight. BMJ 2017;358:j3437. [Ref.ID 101980]
17.
Hampp C, Pippins J. Pioglitazone and bladder cancer: FDA's assessment. Pharmacoepidemiol Drug Saf 2017;26:117-8. [Ref.ID 101950]
19. Cita con resumen
Anónimo. FDA approves guselkumab for treatment of plaque psoriasis. DIA Daily 2017:2. [Ref.ID 101909]
Seleccionar todas
 
 1 a 20 de 3005 siguiente >>